EvidentIQ

EvidentIQ Group designs and operates purpose-built eClinical software to support the full lifecycle of clinical research. Serving pharmaceutical companies, biotechs, contract research organisations (CROs), academic institutions, medical device manufacturers, and registry operators, EvidentIQ's platforms enable efficient, compliant, and data-driven clinical programmes with built-in GxP and 21 CFR Part 11 controls. The group integrates practical AI into core clinical workflows to improve data quality, reduce manual effort, and support reliable decision-making.

With roots tracing back to 1997 and over 20 years of combined clinical research experience across its portfolio companies, EvidentIQ Group was formally established in 2021 and has grown through strategic mergers and acquisitions to become a leading provider of modern eClinical solutions. The group's platforms are purpose-built to adapt to study-specific requirements and regulated workflows, improving data accuracy, streamlining processing, and increasing efficiency across clinical operations. EvidentIQ's focus is guided by four core performance parameters: time, cost, quality, and flexibility.

eClinical Platform Portfolio

• Dacima EDC: Founded in 2006 in Montréal, Canada, Dacima delivers a highly configurable Electronic Data Capture platform for complex study designs and regulatory-driven data collection. It features strong subject-facing components, an economical price point, and a pragmatic UI designed to save time. Dacima is primarily used in the USA and Canada, with a focus on CROs, biotechs, academic institutions, and NGOs. It was founded by experts in epidemiology, medical research, and information technology.
• Clindex: Founded in 1997 in Minnesota, USA (originally as Fortress Medical System), Clindex is an inherently integrated EDC, CTMS, and eTMF platform with a strong focus on medical devices, diagnostics, and small biotechs. It provides full control over study data and workflows, configurable dashboards to monitor study progress, tools to identify operational bottlenecks, and structured reporting capabilities.
• Carenity: A digital CRO specialised in patient-centred outcome research and real-world evidence (RWE) generation. Carenity extends EvidentIQ's capabilities by enabling direct patient engagement through established online patient communities. Its PatientLive® solution provides access to a community of over 500,000 patients and caregivers.
• Future for Patients: A patient recruitment service covering feasibility, trial planning, and delivery to help find patients for clinical studies.

Solutions by Customer Segment

• Clinical Research Organisations (CROs): Agile, zero-code platform solutions that empower CROs to manage complex trials efficiently. Dacima seamlessly integrates into existing workflows and is designed to be future-proof.
• Academic Research: An industry-standard solution offering complete independence, cost-effective scalability to any type of study, and a focus on data quality, ease of use, and efficiency.
• Medical Devices: An all-in-one solution that seamlessly connects to medical devices, enabling users to efficiently handle large datasets and reduce turnaround time.
• Biotech: Clindex provides an integrated platform for managing clinical trial operations, bringing EDC, CTMS, and eTMF into a single environment with full workflow control.
• Registries: An affordable, scalable, and compliant platform for launching and managing registries, featuring rapid deployment, real-time analytics, seamless integrations, and dedicated support and consulting. Backed by 20+ years of expertise, EvidentIQ partnered with Movember in 2019 to design a cutting-edge registry database for the world's first cancer registry super network, integrating global patient data from over 130,000 men.
• Pharma Companies: EvidentIQ operates as a digital CRO for pharmaceutical sponsors, combining eClinical technology with deep clinical research expertise to support trial execution, data management, and operational oversight with full visibility across the clinical trial lifecycle.

Core Capabilities and Technology

• Electronic Data Capture (EDC), eCOA, and ePRO solutions for flexible and reliable data collection
• Clinical Trial Management System (CTMS) for operational oversight and workflow coordination
• Electronic Trial Master File (eTMF) for document management and regulatory compliance
• Real-world evidence (RWE) generation and patient-centred outcome research through Carenity
• Data science capabilities and patient recruitment services
• Practical AI integration into core clinical workflows to improve data quality and reduce manual effort
• Built-in GxP and 21 CFR Part 11 compliance controls across all platforms
• Configurable dashboards, real-time analytics, and structured reporting
• EvidentIQ Data Hub launched in 2024, including a partnership with AB Cube to integrate SafetyEasy® safety database software into EDC solutions

Company History and Growth

• 1997: Fortress Medical System (FMS) founded in Minnesota, USA, launching Clindex
• 2002: XClinical founded in Munich, Germany, launching Marvin EDC
• 2006: Dacima Software founded in Montréal, Canada, launching Dacima EDC
• 2020: Marvin, Carenity, and Fortress Medical System merged into one company
• 2021: EvidentIQ Group formally founded; Marvin and Clindex become official brands; Carenity launches PatientLive®
• 2022: Dacima EDC joins the EvidentIQ Group as its third brand
• 2023: Asthenis, experts in tumour documentation, joins the EvidentIQ Group
• 2024: Launch of the EvidentIQ Data Hub and partnership with AB Cube
• 2026: Marvin and Asthenis become part of European-based AB Cube following a strategic transaction

EvidentIQ Group is led by Chief Executive Officer Dominique Manu, Chief Financial Officer Erik Kolb, and Chief Services Officer Jill Tufano. The group's portfolio of platforms allows organisations to define the appropriate level of flexibility, integration, and patient involvement for their clinical research strategy, while maintaining scientific rigour and regulatory compliance across all studies.